CEO Warns of Slower 2027 Growth as Rivals Threaten Omnipod Share
PODD sits 28% above its 52-week low of $126.4.
Summary
CEO Ashley McEvoy told the Q3 call that Insulet will take a more conservative view of 2027, with revenue growth slowing as the base gets larger, Omnipod 6 launches, and new insulin pump competitors enter. She conceded rivals could take a few percentage points of market share. That forward caution is the negative offset to an otherwise strong quarter reported earlier today: revenue of $842M (+19.2%) beat the high end of guidance, adjusted EPS of $1.99 beat the $1.59 estimate, and the company raised the low end of FY26 revenue guidance to $3.277B while lifting its adjusted operating margin outlook to about 150bps of expansion. The board also approved a $1 billion buyback, with roughly $400M expected in Q4 funded from existing cash. The stock gained Wednesday on the results, but the 2027 share-loss commentary is the first explicit management acknowledgment that the competitive moat is narrowing.
At the time of this announcement, PODD was trading at $162.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.3B. The 52-week trading range was $126.40 to $354.88. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Benzinga.